By Connor Hart
Adobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading.
Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in postmarket trading.
DBV Technologies confirmed alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3. The biopharmaceutical company said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size, wear time collection methodology and analysis. It expects to submit a biologics license application for the toddlers' indication of the Viaskin Peanut Patch in the second half of 2026. Shares surge 28%, to $4.20, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 11, 2024 18:40 ET (23:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。